← Back to Screener
Prothena Corporation plc Ordinary Shares (PRTA)
Price$10.52
Favorite Metrics
Price vs S&P 500 (26W)0.56%
Price vs S&P 500 (4W)20.14%
Market Capitalization$580.05M
All Metrics
Book Value / Share (Quarterly)$5.21
P/TBV (Annual)1.02x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-43.57%
Cash Flow / Share (Quarterly)$-3.04
Price vs S&P 500 (YTD)10.66%
Net Profit Margin (TTM)-2520.57%
EPS (TTM)$-4.53
10-Day Avg Trading Volume0.46M
EPS Excl Extra (TTM)$-4.53
Revenue Growth (5Y)60.83%
EPS (Annual)$-4.53
ROI (Annual)-87.03%
Net Profit Margin (5Y Avg)-591.09%
Cash / Share (Quarterly)$5.71
Revenue Growth QoQ (YoY)-99.01%
ROA (Last FY)-74.69%
Revenue Growth TTM (YoY)-92.83%
EBITD / Share (TTM)$-3.98
ROE (5Y Avg)-28.55%
Operating Margin (TTM)-2216.44%
Cash Flow / Share (Annual)$-3.04
P/B Ratio2.07x
P/B Ratio (Quarterly)1.83x
Net Income / Employee (Annual)$-4
EV / Revenue (TTM)28.14x
Net Interest Coverage (TTM)-1575.00x
ROA (TTM)-62.04%
EV / EBITDA (TTM)4.07x
EPS Incl Extra (Annual)$-4.53
Current Ratio (Annual)7.72x
Quick Ratio (Quarterly)7.57x
3-Month Avg Trading Volume0.57M
52-Week Price Return8.85%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.66
P/S Ratio (Annual)59.90x
Asset Turnover (Annual)0.03x
52-Week High$11.69
Operating Margin (5Y Avg)-549.63%
EPS Excl Extra (Annual)$-4.53
CapEx CAGR (5Y)-7.15%
Tangible BV CAGR (5Y)8.84%
26-Week Price Return4.54%
Quick Ratio (Annual)7.57x
13-Week Price Return21.44%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.72x
Enterprise Value$272.519
Revenue / Share Growth (5Y)51.42%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)2.47%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2073.82%
Cash / Share (Annual)$5.71
3-Month Return Std Dev46.43%
Net Income / Employee (TTM)$-4
ROE (Last FY)-87.03%
EPS Basic Excl Extra (Annual)$-4.53
P/FCF (TTM)23.37x
Receivables Turnover (TTM)52.40x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.53
Receivables Turnover (Annual)52.40x
ROI (TTM)-73.00%
P/S Ratio (TTM)59.90x
Pretax Margin (5Y Avg)-508.41%
Revenue / Share (Annual)$0.18
Tangible BV / Share (Annual)$7.15
Forward P/E42.65x
Price vs S&P 500 (52W)-20.98%
Year-to-Date Return13.30%
5-Day Price Return2.27%
EPS Normalized (Annual)$-4.53
ROA (5Y Avg)-24.52%
Net Profit Margin (Annual)-2520.57%
Month-to-Date Return11.32%
Cash Flow / Share (TTM)$-1.36
EBITD / Share (Annual)$-3.98
Operating Margin (Annual)-2216.44%
ROI (5Y Avg)-28.55%
EPS Basic Excl Extra (TTM)$-4.53
P/TBV (Quarterly)1.01x
P/B Ratio (Annual)1.83x
Pretax Margin (TTM)-2073.82%
Book Value / Share (Annual)$5.21
Price vs S&P 500 (13W)20.75%
Beta-0.32x
P/FCF (Annual)6.30x
Revenue / Share (TTM)$0.18
ROE (TTM)-73.00%
52-Week Low$4.32
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.77
3.77
3.77
3.75
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PRTAProthena Corporation plc Ordinary Shares | 59.90x | -92.83% | — | — | $10.52 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Prothena is a late-stage clinical biotechnology company developing treatments for neurodegenerative and amyloid diseases using its proprietary CYTOPE platform, which targets intracellular disease pathways in the brain and body. The company's pipeline includes Prasinezumab for Parkinson's disease, Coramitug for ATTR amyloidosis, and partnered programs targeting Alzheimer's disease and ALS. Prothena combines wholly-owned and partnered assets to address protein-dysregulation disorders with significant unmet medical needs.